Methods and uses for dendritic cell therapy
This invention provides methods of evaluating immune system parameters to identify and treat patients who are likely to experience more favorable treatment outcomes. This invention also provides methods for treating a human patient with a dendritic cell therapy by obtaining at least one value or measurement of the level and/or amount of a particular type of treatment indicator in the patient, confirming that said value or measurement exceeds or is less than the treatment threshold value for that value or measurement, and administering said dendritic cell therapy to the patient.
1. A method for treating a cancer patient with a dendritic cell vaccine comprising the steps of:
a) obtaining a count of the regulatory T cells (Tregs) per unit volume in the blood of said patient;
b) confirming that said count exceeds a treatment threshold value of Tregs per unit volume; and
c) administering said dendritic cell vaccine to said patient, wherein said treatment threshold value exceeds 500 Tregs/100 microliters of whole blood or an equivalent measurement.
2. The method of claim 1 , wherein said dendritic cell vaccine comprises PME-CD40L mature dendritic cells (DCs) that are loaded with an antigen.
3. The method of claim 2 , wherein said DCs are loaded with said antigen by transfection with RNA encoding said antigen.
4. The method of claim 3 , wherein said RNA is prepared from cancer cells of said patient.
5. The method of claim 1 , wherein said Tregs are identified as CD4+, CD25+, and one of FoxP3+ or CD127−.
6. The method of claim 1 , wherein said Tregs are identified as CD4+, CD25+, FoxP3+, and CD127−.
7. The method of claim 1 , wherein said treatment threshold value exceeds 650 Tregs/100 microliters of whole blood or an equivalent measurement.
8. A method of determining whether an immune response was induced in a patient by a treatment, comprising the steps of:
a) quantifying the number of regulatory T cells (Tregs) and/or Treg effector cells (Treg/eff cells) present in a sample of a patient's blood to establish a baseline reading;
b) following administration to said patient of a treatment, quantifying the number of Tregs and/or Treg/eff cells present in the sample of said patient's blood to establish a post-treatment reading;
c) comparing said baseline reading and said post-treatment reading to determine whether the frequency or amount of Tregs and/or Treg/eff cells present in the sample of the patient's blood has increased;
wherein a significant decrease in the frequency or amount of Tregs and/or a significant increase in the frequency or amount of Treg/eff cells indicates that the immune response was induced in the patient, wherein said patient is selected for the treatment by:
a) obtaining a count of the Trees per unit volume in the blood of said patient; and
b) confirming that said count exceeds a treatment threshold value of Tress per unit volume,
wherein said treatment threshold value exceeds 500 Tregs/100 microliters of whole blood or an equivalent measurement.
9. The method of claim 8 , wherein said treatment comprises administering to said patient autologous mature DCs prepared in vitro.
10. The method of claim 8 , wherein said treatment comprises administering to said patient a dendritic cell vaccine which comprises PME-CD40L mature DCs that are loaded with an antigen.
11. The method of claim 8 , wherein said Tregs are identified as CD4+, CD25+, and one of FoxP3+ or CD127−.
12. The method of claim 8 , wherein said Tregs are identified as CD4+, CD25+, FoxP3+, and CD127−.
13. The method of claim 8 , wherein said treatment threshold value exceeds 650 Tregs/100 microliters of whole blood or an equivalent measurement.
14. A method for administering a dendritic cell vaccine to a patient comprising the steps of:
a) obtaining a count of the regulatory T cells (Tregs) per unit volume in the blood of said patient;
b) confirming that said count exceeds a treatment threshold value of Tregs per unit volume; and
c) administering said dendritic cell vaccine to said patient, wherein said treatment threshold value exceeds 500 Tregs/100 microliters of whole blood or an equivalent measurement.
15. The method of claim 14 , wherein said dendritic cell vaccine comprises PME-CD40L mature dendritic cells (DCs) that are loaded with an antigen.
16. The method of claim 15 , wherein said DCs are loaded with said antigen by transfection with RNA encoding said antigen.
17. The method of claim 16 , wherein said RNA is prepared from cancer cells of said patient.
18. The method of claim 14 , wherein said Tregs are identified as CD4+, CD25+, and one of FoxP3+ or CD127−.
19. The method of claim 14 , wherein said Tregs are identified as CD4+, CD25+, FoxP3+, and CD127−.
20. The method of claim 14 , wherein said treatment threshold value exceeds 650 Tregs/100 microliters of whole blood or an equivalent measurement.